Advert - Boehringer Ingelheim

• Date posted
  12 March 2021
• Sanction
  Advertisement,
• Case number/s
  AUTH/3293/1/20 - Anonymous v Boehringer Ingelheim

For a misleading claim that Pradaxa 110mg (dabigatran) could be used in any patient at increased risk of bleeding when it was contraindicated in those with severe renal impairment, which risked patient safety, Boehringer Ingelheim was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 7.2 - Making a misleading claim

Clause 9.1 - Failing to maintain high standards.